For your appropriate adult VWD patients

Trial Program
TAKEDA's FREEDOM OF CHOICE™ Free Trial program offers eligible patients 3 free doses of VONVENDI® [von Willebrand factor (Recombinant)] with or without rFVIII.

*Free Trial Program is for new VONVENDI patients only. Participants must receive consultation and approval from a healthcare provider.

Download Registration Form
Hematology Support Center logo.

Hematology Support Center
Takeda's HSC provides patients and caregivers with information, guidance, and resources regarding their treatment.

  • Insurance education & support
  • CoPay assistance for eligible patients
  • Medicare & Medicaid information
  • Advocacy & disease information resources
  • Record-keeping tools & worksheets
  • HTC directories
  • Toll-free HSC team contact hotline
  • Healthcare Educators (HCEs) available to provide disease state and product education
Go To HSC

Specialized patient education
Additional Takeda team members are available for more specialized assistance:

  • Bilingual Community Educators (BCEs): Takeda’s BCE team can assist patients and caregivers for whom English is a second language
Register for updates.

Register For Updates

Stay up to date with the latest news and information

Sign Up Now
Find support for healthcare professionals.

For Healthcare Professionals

Get the support you need to help your patients and your team

Get Support
Contact a Takeda rep.

Contact a Takeda Rep

Get in touch with a Takeda representative in your area

Sign Up Now

Indications

VONVENDI [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (rVWF) indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding

Detailed Important Risk Information
CONTRAINDICATIONS

Do not use in patients who have had life-threatening hypersensitivity reactions to VONVENDI or its components (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins).

WARNINGS AND PRECAUTIONS

Embolism and Thrombosis

Thromboembolic reactions, including disseminated intravascular coagulation, venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, can occur, particularly in patients with known risk factors for thrombosis, including low ADAMTS13 levels. Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope, and institute prophylaxis measures against thromboembolism based on current recommendations.

In patients requiring frequent doses of VONVENDI in combination with recombinant factor VIII, monitor plasma levels for FVIII:C activity because sustained excessive factor VIII plasma levels can increase the risk of thromboembolic events.

One out of 80 subjects treated with VONVENDI in clinical trials developed proximal deep vein thrombosis in perioperative period after total hip replacement surgery.

Hypersensitivity Reactions

Hypersensitivity reactions have occurred with VONVENDI. These reactions can include anaphylactic shock, generalized urticaria, angioedema, chest tightness, hypotension, shock, lethargy, nausea, vomiting, paresthesia, pruritus, restlessness, blurred vision, wheezing and/or acute respiratory distress. Discontinue VONVENDI if hypersensitivity symptoms occur and administer appropriate emergency treatment.

Neutralizing Antibodies (Inhibitors)

Inhibitors to VWF and/or factor VIII can occur. If the expected plasma levels of VWF activity (VWF:RCo) are not attained, perform an appropriate assay to determine if anti-VWF or anti-factor VIII inhibitors are present. Consider other therapeutic options and direct the patient to a physician with experience in the care of either VWD or hemophilia A.

In patients with high levels of inhibitors to VWF or factor VIII, VONVENDI therapy may not be effective and infusion of this protein may lead to severe hypersensitivity reactions. Since inhibitor antibodies can occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors.

ADVERSE REACTIONS

In clinical trials, the most common adverse reactions observed in ≥2% of subjects (n=80) were generalized pruritus, vomiting, nausea, dizziness, and vertigo.

One subject treated with VONVENDI in perioperative setting developed deep vein thrombosis after total hip replacement surgery.

Please see VONVENDI full Prescribing Information.